FLT3 and acute myeloid leukemia: Early phase I and retrospective studies of sorafenib monotherapy in R/R AML irrespective of FLT3 status demonstrated acceptable toxicity profiles but mixed CR rates, ranging from 10 to 48% (35, 36).